Walvax BioTech (300142.SZ) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · China · ISIN CNE100000WN2
Walvax BioTech financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 2.82 bn CNY | 2.41 bn CNY |
| Gross profit | 2.08 bn CNY | 1.66 bn CNY |
| Operating income | 96.67 m CNY | 69.96 m CNY |
| EBIT | 24.01 m CNY | 69.96 m CNY |
| Net income | 142.16 m CNY | 177.74 m CNY |
Full history since 2007, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Walvax BioTech
Walvax Biotechnology Co., Ltd., engages in the research and development, manufacture, and distribution of vaccines in China and internationally. Its vaccine portfolio includes recombinant human papillomavirus bivalent, 13-valent pneumococcal polysaccharide conjugate, 23-valent pneumococcal polysaccharide, group ACYW135 meningococcal polysaccharide, group A and C meningococcal polysaccharide, group A and group C meningococcal conjugate, and haemophilus influenzae type b conjugate vaccines, as well as diphtheria, tetanus and acellular pertussis combined vaccine. The company was founded in 2001 and is headquartered in Kunming, China.
More stocks
- Guangzhou Baiyun International Airport Co Ltd (600004.SS)
- Shandong Weifang Rainbow Chemical Co. Ltd (301035.SZ)
- SIMMTECH Co. Ltd (222800.KQ)
- Keda Clean Energy Co Ltd (600499.SS)
- Solusi Tunas Pratama Tbk (SUPR.JK)
- AMERICAN EAGLE OUTFITTERS INC (AEO)
- DigitalBridge Group, Inc. (DBRG)
- AtriCure, Inc. (ATRC)
- Sugi Holdings Co Ltd (7649.T)
- Shanghai M&G Stationery Inc (603899.SS)
- Mobimo Holding AG (MOBN.SW)
- Tarsus Pharmaceuticals, Inc. (TARS)
Not investment advice. All data without warranty, price as of 23.10.2026. Details in the risk notice.